Women’s Cancers Research
In vitro disease models predicted advantages for use of 1/2-1/4 standard cytotoxic doses and selection of drugs each of which simultaneously interact with multiple drugs.
Anticancer research
Targeted therapy added to cores of previously failed drugs has similarly produced responses of refractory pancreatic cancer.
Women’s Cancers Research
The use of Bevacizumab (Bev) for ovarian cancer (OC) has been impeded by adverse events (AEs), long maintenance therapy (T) and tumor rebound. Eligibility, requirements and limits, as well as ideal time(s) and length of use remain unknowns. Drug interactions and algorithms offer testable solutions.
Gastrointestinal Cancers
Routine blood tests are prognostic tests for patients with cholangiocarcinoma. New drug regimens...
.png)
